성장을 멈추지 마세요

체험은 만족하셨나요?

현재 45,766명이 마이메르시로 공부 중이에요

지식 자료를 소장하고 멋진 의료인으로 성장하세요

학습 자료 둘러보기 →
Fetal Alcohol Spectrum Disorders (FASDs) | 마이메르시 MyMerci
제안하기

뭔가 하고 싶은 말이 있는거야?

0 / 2000
컨텐츠 수정하기

컨텐츠 내용을 수정할 수 있습니다

수정하기
닫기

Fetal Alcohol Spectrum Disorders (FASDs)

NCLEX Review Guide: Newborn of a Mother with HIV

Pathophysiology and Transmission

Vertical Transmission of HIV

  • HIV can be transmitted from mother to infant during pregnancy (in utero), during labor and delivery, or through breastfeeding. Without intervention, the risk of transmission ranges from 15-45% depending on factors such as maternal viral load, duration of ruptured membranes, and mode of delivery.
  • The majority of perinatal HIV transmissions (60-70%) occur during labor and delivery when the infant is exposed to maternal blood and genital secretions. In utero transmission accounts for approximately 20-30% of cases, while breastfeeding can contribute an additional 10-15% risk.

Key Points

  • Most vertical HIV transmission occurs during labor and delivery, not during pregnancy.
  • Without intervention, the risk of mother-to-child transmission is 15-45%.

Risk Factors for Transmission

  • The single most important risk factor for perinatal HIV transmission is high maternal viral load. Other significant risk factors include low maternal CD4+ count, advanced maternal disease, prolonged rupture of membranes (>4 hours), preterm birth, and invasive procedures during pregnancy or delivery.
  • Chorioamnionitis, placental disruption, and maternal co-infections (such as sexually transmitted infections) can increase the risk of transmission by causing inflammation and compromising placental integrity.

Key Points

  • Maternal viral load is the strongest predictor of vertical transmission risk.
  • Prolonged rupture of membranes (>4 hours) significantly increases transmission risk.

Prevention and Management

Antiretroviral Prophylaxis

  • All HIV-exposed newborns should receive antiretroviral prophylaxis as soon as possible after birth, ideally within 6-12 hours. The standard regimen is oral zidovudine (AZT) for 4-6 weeks, but high-risk infants may receive a multi-drug regimen that includes nevirapine.
  • The dosing of zidovudine is based on gestational age and birth weight, with preterm infants requiring adjusted dosing schedules. Nurses must carefully calculate and administer the correct dose to prevent medication errors.

Key Points

  • Antiretroviral prophylaxis should begin within 6-12 hours after birth.
  • Zidovudine (AZT) is the standard prophylactic medication, administered for 4-6 weeks.

Feeding Recommendations

  • In developed countries with access to clean water and formula, HIV-positive mothers should completely avoid breastfeeding regardless of viral load or antiretroviral therapy status. Formula feeding eliminates the risk of HIV transmission through breast milk.
  • In resource-limited settings where formula feeding may not be safe or feasible, exclusive breastfeeding with maternal antiretroviral therapy is recommended, as mixed feeding (combining breast milk and formula/other foods) increases transmission risk compared to exclusive breastfeeding.

Key Points

  • In the United States and other developed countries, HIV-positive mothers should exclusively formula feed.
  • Mixed feeding carries a higher transmission risk than exclusive breastfeeding in settings where formula is not feasible.

Delivery Considerations

  • Scheduled cesarean delivery at 38 weeks gestation is recommended for HIV-positive women with viral loads >1,000 copies/mL near delivery to reduce transmission risk. For women with viral loads <1,000 copies/mL on antiretroviral therapy, vaginal delivery is considered safe.
  • During labor and delivery, invasive procedures such as fetal scalp electrodes, fetal scalp sampling, and instrumental delivery should be avoided whenever possible to minimize fetal exposure to maternal blood and secretions.

Key Points

  • Cesarean delivery is recommended for maternal viral loads >1,000 copies/mL.
  • Avoid invasive monitoring procedures during labor to reduce transmission risk.

Newborn Assessment and Testing

Diagnostic Testing Protocol

  • HIV-exposed newborns require virologic testing (HIV DNA or RNA PCR) at 14-21 days of life, 1-2 months, and 4-6 months. Standard antibody tests are not useful in infants younger than 18 months because maternal antibodies cross the placenta and can yield false-positive results.
  • Definitive exclusion of HIV infection requires two or more negative virologic tests, with one obtained after 1 month of age and one after 4 months of age. HIV infection can be presumptively excluded with two negative virologic tests, one at ≥14 days and one at ≥4 weeks of age.

Key Points

  • Use HIV DNA or RNA PCR tests for diagnosis in infants, not antibody tests.
  • Testing should occur at 14-21 days, 1-2 months, and 4-6 months of age.

Clinical Assessment

  • HIV-exposed newborns may appear completely normal at birth, as signs of infection typically develop over time if the infant is infected. Regular assessment for failure to thrive, recurrent infections, lymphadenopathy, hepatosplenomegaly, and oral thrush is essential during follow-up visits.
  • Nurses should perform comprehensive physical assessments at each healthcare visit, with particular attention to growth parameters, developmental milestones, and signs of opportunistic infections. Early recognition of symptoms allows for prompt intervention.

Key Points

  • HIV-exposed newborns typically appear normal at birth, even if infected.
  • Monitor for failure to thrive, recurrent infections, and oral thrush during follow-up.

Immunization Considerations

  • HIV-exposed but uninfected infants should receive all routine immunizations according to the recommended schedule. HIV-infected infants should receive all inactivated vaccines according to the routine schedule but have special considerations for live vaccines.
  • The BCG vaccine (used in some countries) and oral polio vaccine are contraindicated in HIV-infected children. MMR and varicella vaccines may be administered to HIV-infected children who are not severely immunocompromised.

Key Points

  • HIV-exposed uninfected infants follow standard immunization schedules.
  • Live vaccines may be contraindicated in HIV-infected infants depending on immune status.

Nursing Care

Medication Administration

  1. Calculate the correct dose of zidovudine (AZT) based on the infant's gestational age and weight.
  2. Administer oral zidovudine using an oral syringe to ensure accurate dosing.
  3. Document the medication administration, including dose, route, time, and infant's response.
  4. Monitor for potential side effects including anemia, neutropenia, and gastrointestinal disturbances.
  5. Ensure caregivers understand medication administration technique before discharge.

Key Points

  • Accurate dosing of antiretroviral medications is critical to prevent toxicity and ensure efficacy.
  • Monitor complete blood count (CBC) for medication-induced cytopenias.

Discharge Planning and Follow-up

  • Comprehensive discharge planning for HIV-exposed newborns includes medication teaching, feeding instructions, follow-up appointment scheduling, and connecting families with appropriate support services. The nurse should verify that caregivers can demonstrate medication administration technique.
  • Follow-up care involves coordination between pediatric infectious disease specialists, primary care providers, and social services to ensure adherence to the testing schedule, medication regimen, and regular health maintenance visits.

Key Points

  • Ensure caregivers can demonstrate medication administration before discharge.
  • Coordinate follow-up with infectious disease specialists and primary care.

Psychosocial Support

  • Mothers with HIV may experience significant guilt, fear, anxiety, and stigma related to their diagnosis and the potential impact on their newborn. Nurses should provide non-judgmental support and accurate information about current transmission rates with proper interventions.
  • Confidentiality is paramount when caring for HIV-affected families. Information about maternal HIV status should be shared only with healthcare providers directly involved in the care of the mother and infant, and all documentation should follow institutional privacy protocols.

Key Points

  • Provide emotional support and accurate information to reduce maternal anxiety.
  • Maintain strict confidentiality regarding maternal HIV status.

Clinical Scenario

A 28-year-old woman with HIV delivers a full-term male infant via cesarean section due to a viral load of 3,500 copies/mL. She received antiretroviral therapy throughout pregnancy and intravenous zidovudine during labor. The infant appears healthy with normal vital signs and physical examination. As the nurse caring for this newborn:

  1. Initiate oral zidovudine within 6 hours of birth at appropriate weight-based dosing
  2. Provide formula and educate mother to avoid breastfeeding completely
  3. Arrange for first HIV PCR test at 14-21 days of life
  4. Teach mother about medication administration, follow-up schedule, and signs of medication side effects
  5. Provide emotional support and connect family with appropriate resources

Summary of Key Points

  • Without intervention, the risk of mother-to-child HIV transmission is 15-45%, with most transmission occurring during labor and delivery.
  • All HIV-exposed newborns should receive antiretroviral prophylaxis, typically zidovudine for 4-6 weeks, starting within 6-12 hours of birth.
  • HIV-exposed infants should be exclusively formula-fed in developed countries to eliminate transmission risk through breast milk.
  • Diagnostic testing uses HIV DNA or RNA PCR at 14-21 days, 1-2 months, and 4-6 months; antibody tests are not reliable until after 18 months of age.
  • Comprehensive care includes medication administration, feeding guidance, follow-up testing, immunizations, and psychosocial support.

Commonly Confused Points

Concept Correct Understanding Common Misconception
HIV Testing in Infants Use HIV DNA or RNA PCR tests for diagnosis in infants under 18 months Using HIV antibody tests, which detect maternal antibodies and give false positives
Breastfeeding Recommendations Complete avoidance of breastfeeding in developed countries regardless of maternal viral load Believing low viral load makes breastfeeding safe in developed countries
Antiretroviral Prophylaxis Timing Start within 6-12 hours of birth for maximum effectiveness Delaying initiation beyond 12 hours, reducing effectiveness
Cesarean Delivery Indications Recommended for viral loads >1,000 copies/mL Believing all HIV-positive women require cesarean delivery regardless of viral load
Immunization Schedule HIV-exposed uninfected infants follow standard schedule; HIV-infected infants have special considerations for live vaccines Withholding routine immunizations due to HIV exposure

Study Tips

Memory Aids

HIV Transmission Prevention "AZT"

A - Antiretrovirals (maternal during pregnancy, labor; infant prophylaxis)
Z - Zero breastfeeding in developed countries
T - Timing of cesarean delivery at 38 weeks for high viral loads

HIV Testing Schedule "1-2-4"

1 - First test at 14-21 days
2 - Second test at 1-2 months
4 - Final test at 4-6 months

Risk Factors "VIRAL"

V - Viral load (high maternal viral load)
I - Immunosuppression (low maternal CD4+ count)
R - Rupture of membranes (prolonged)
A - Advanced disease in mother
L - Labor procedures (invasive procedures)

Common Pitfalls

Medication Dosing: Zidovudine dosing for infants is based on gestational age and weight. Using adult dosing or failing to adjust for prematurity can lead to toxicity.

Testing Interpretation: Don't confuse a negative PCR test at birth with definitive exclusion of infection. HIV may not be detectable immediately after birth, requiring the full testing schedule.

Confidentiality Breaches: Discussing maternal HIV status with extended family or hospital staff not directly involved in care violates privacy and can lead to stigmatization.

Quick Check Questions

1. Which diagnostic test is most appropriate for detecting HIV infection in a 6-week-old infant?

Answer: HIV DNA or RNA PCR test

2. What is the recommended feeding method for HIV-exposed infants in the United States?

Answer: Exclusive formula feeding

3. When should antiretroviral prophylaxis be initiated in an HIV-exposed newborn?

Answer: Within 6-12 hours after birth

4. What is the primary factor determining whether an HIV-positive woman should have a cesarean delivery?

Answer: Maternal viral load >1,000 copies/mL near delivery

Self-Assessment Checklist

I can describe the three potential routes of vertical HIV transmission
I can identify the major risk factors for mother-to-child transmission
I understand the antiretroviral prophylaxis protocol for HIV-exposed newborns
I can explain the appropriate feeding recommendations for HIV-exposed infants
I know the HIV testing schedule for exposed infants
I can differentiate between appropriate diagnostic tests for infants vs. adults
I understand the immunization considerations for HIV-exposed and infected infants
I can identify key components of discharge planning for HIV-exposed newborns
I recognize the importance of psychosocial support and confidentiality
I can identify potential side effects of antiretroviral prophylaxis in newborns

Remember that with current interventions, the risk of mother-to-child HIV transmission can be reduced to less than 1%. Your nursing care plays a crucial role in achieving this outcome and supporting families affected by HIV.

다음 이론을 계속 학습하려면 로그인하세요.

로그인하고 계속 학습
컨텐츠를 그만볼래?

필기노트, 하이라이터, 메모는 잘 쓰고 있어?

내보내줘
어떤 폴더에 저장할래?

컨텐츠 노트에는 총 0개의 폴더가 있어!

폴더 만들기
컨텐츠 만들기
만들기
신고했어요.

운영진이 검토할게요!

해당 유저를 차단했어요.

마이페이지에서 차단한 회원을 관리할 수 있어요.